Bayer meets its rivals!

A few days ago, the official website of the State Food and Drug Administration showed that the Nifedipine Sustained-Release Tablets (I) of Jiangsu Pharmaceutical of Yangtze River Pharmaceutical Group was approved as a supplementary application
.

Data show that as a commonly used CCB antihypertensive drug in clinical practice, nifedipine is a first-line drug recommended by relevant guidelines at home and abroad.
Compared with the general release dosage form, nifedipine sustained-release tablets make the antihypertensive effect more stable and have lower side effects.
The effect lasts longer and the clinical advantage is more obvious
.

Sales of terminal nifedipine tablets in China's public medical institutions in recent years (unit: 100 million yuan)

Source: The terminal competition pattern of China's public medical institutions

According to data from Menet.
com, in 2020, the total sales of nifedipine tablets in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and the terminals of Chinese urban physical pharmacies exceed 8 billion yuan.
, China’s public medical institution terminals are the main sales channel for this product, and sales in the first half of 2021 will increase by 25.
48% year-on-year; while the physical drugstore terminals in cities in China are expected to increase by 1.
69% year-on-year in 2021
.

Nifedipine tablets review situation

Source: One-click search on Mi Nei.
com

The main products of nifedipine tablets include nifedipine controlled-release tablets, nifedipine sustained-release tablets (Ⅰ), nifedipine sustained-release tablets (Ⅱ), etc.
, involving Bayer, Qingdao Huanghai Pharmaceutical, Shanghai Modern Pharmaceutical, China Resources Double Crane Limin Pharmaceutical (Jinan) and many other companies, among which Bayer has the largest market share
.

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

As of now, Yangtze River has 76 varieties (102 product regulations) reviewed, of which, there are 8 varieties (10 product regulations) for cardiovascular system drugs
.

Source: official website of the State Food and Drug Administration, Mi Nei.
com database

Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.